Present improvements showed that SEMA3B‐AS1 expression was decreased in triple‐negative breast cancer, gastric cardia adenocarcinoma, and esophageal squamous cell carcinoma,16, 17, 18 and low SEMA3B‐AS1 expression levels were closely associated with poor survival in breast cancer and hepatocellular carcinoma.19, 20. Here, SEMA3B is linked to breast carcinoma.